Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS)

• by Sundas Ejaz Maqsood, John William Posnett, Mohamed Elalfy

• June 4, 2026

Let The Light In

New study examines how much light from light-based myopia therapies actually reaches the intended ocular tissues

• June 3, 2026

• 3 min

Gene Therapy Reaches XLRS Milestone

Atsena Therapeutics reports positive interim data for XLRS gene therapy

• May 25, 2026

• 3 min

Dual Light Therapy Device for Dry Eye and OSD Management

Essilor Instruments' eye-light® delivers targeted, condition-specific management for ocular surface diseases

• June 2, 2026

• 2 min